Genmab Research and Development Expenses 2019-2025 | GMAB

Genmab research and development expenses for the twelve months ending March 31, 2025 were $1.437B, a 20.59% increase year-over-year.

  • Genmab annual research and development expenses for 2024 were $1.413B, a 27.58% increase from 2023.
  • Genmab annual research and development expenses for 2023 were $1.108B, a 40.67% increase from 2022.
  • Genmab annual research and development expenses for 2022 were $0.788B, a 18.4% increase from 2021.

Genmab Research and Development Expenses 2019-2025 | GMAB

  • Genmab annual research and development expenses for 2024 were $1.413B, a 27.58% increase from 2023.
  • Genmab annual research and development expenses for 2023 were $1.108B, a 40.67% increase from 2022.
  • Genmab annual research and development expenses for 2022 were $0.788B, a 18.4% increase from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$220.6B
Amgen (AMGN)$158.8B
Gilead Sciences (GILD)$136.4B
Vertex Pharmaceuticals (VRTX)$120.4B
Bristol Myers Squibb (BMY)$95.4B
GSK (GSK)$78.4B
CSL (CSLLY)$76.6B
Regeneron Pharmaceuticals (REGN)$61.3B
Alnylam Pharmaceuticals (ALNY)$41.1B
Argenex SE (ARGX)$34.3B
BioNTech SE (BNTX)$27.1B
Royalty Pharma (RPRX)$20.2B
Biogen (BIIB)$19.7B
Insmed (INSM)$18.6B
Illumina (ILMN)$15.7B
Genmab (GNMSF)$14.2B
Incyte (INCY)$13.3B
Moderna (MRNA)$13B
Exelixis (EXEL)$12.2B
BioMarin Pharmaceutical (BMRN)$11.1B
QIAGEN (QGEN)$10.7B
Ascendis Pharma (ASND)$10.7B
Swedish Orphan Biovitrum (BIOVF)$10.4B
Exact Sciences (EXAS)$9.8B
Verona Pharma American Depositary Share (VRNA)$8.9B
Bio-Techne Corp (TECH)$8.5B
Blueprint Medicines (BPMC)$8.4B
Roivant Sciences (ROIV)$7.7B
Repligen (RGEN)$7.3B
Regencell Bioscience Holdings (RGC)$7.3B